12400 High Bluff Drive
197 articles about Evofem Biosciences
Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).
Evofem Biosciences, Inc. announced another new insurance win that gives millions of additional women access to Phexxi® for the prevention of pregnancy.
Evofem Biosciences, Inc. announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.
Evofem Biosciences, Inc., reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip , a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors.
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women.
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals
Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections for birth control coverage under the Affordable Care Act (ACA).
Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022
Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows.
Evofem Biosciences, Inc., announced a series of industry awards and recognition for the company's direct-to-consumer advertising campaign, House Rules.
Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United States.
Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act
Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.
Evofem Biosciences, Inc., announced an agreement between Evofem and a360 Media under which Phexxi® branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S.
Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health
Evofem Biosciences, Inc., announced that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products, a peer-reviewed article defining and reconfirming the mechanism of action of Phexxi®.
Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides."
Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®
Evofem Biosciences, Inc., announced it has reached an agreement with one of the nation's largest pharmacy benefit managers to ensure most women covered by this plan can fill their Phexxi® prescriptions for pregnancy prevention, without restrictions such as prior authorization or step therapy.
Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy.
Evofem Biosciences, Inc. announced that the U.S. Food and Drug Administration has formally extended the shelf life of Phexxi® from three to four years.
Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock.
Evofem Biosciences, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®
Evofem Biosciences, Inc., announced it has selected Bora Pharmaceuticals Services Inc. Canada as Evofem's new contract manufacturing organization.